Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 trial of Cadonilimab combined with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer

Next Previous
Search
Trial Profile

Phase 3 trial of Cadonilimab combined with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 11 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cadonilimab (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Sponsors Akeso Biopharma

    • Most Recent Events

    • 11 Jan 2022 New trial record
    • 03 Jan 2022 According to an Akeso media release, company obtained approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China to initiate this clinical trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top